Meeting
2013 Genitourinary Cancers Symposium
SGN-75 in the treatment of patients with CD70-positive malignancies including metastatic renal cell carcinoma.
Authors
John A. Thompson
Seattle Cancer Care Alliance, Seattle, WA
John A. Thompson , Andres Forero , Elisabeth I. Heath , Sumanta Kumar Pal , Stephen Maxted Ansell , Jeffrey R. Infante , Sven De Vos , Paul A. Hamlin , Nancy Cherry Whiting , Baiteng Zhao , Nizar M. Tannir
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Renal Cancer
Track
Renal Cell Cancer
Sub Track
Renal Cell Cancer
Clinical Trial Registration Number
NCT01015911
Citation
J Clin Oncol 31, 2013 (suppl 6; abstr 368)
DOI
10.1200/jco.2013.31.6_suppl.368
Abstract #
368
Poster Bd #
C5
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
CD70 is a promising CAR-T cell target in patients with advanced renal cell carcinoma.
First Author: Huihui Ye
Poster
2017 ASCO Annual Meeting
Dose escalation results of a phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in patients (Pts) with relapsed/refractory (r/r) acute myeloid leukemia (AML).
First Author: Harry Paul Erba
Poster
2024 ASCO Annual Meeting
First-in-human study of RLY-2608, a pan-mutant and isoform selective PI3Kα inhibitor, as a single agent in patients (pts) with advanced solid tumors and in combination with fulvestrant in pts with advanced breast cancer.
First Author: Cristina Saura
Poster
2024 ASCO Genitourinary Cancers Symposium
A phase I/II, open label, single arm study on safety, tolerability and anti-tumour effiacy of orellanine treatment in patients with metastatic clear-cell or papillary renal cell carcinoma.
First Author: Sven Lundstam